Uncovering the Potential of CD40 Agonism to Enhance Immune Checkpoint Blockade

被引：2
|
作者：
Wu, Richard C. [1 ,2 ]
Luke, Jason J. [3 ,4 ]
机构：
[1] Ohio State Univ, James Comprehens Canc Ctr, Columbus, OH 43210 USA
[2] Div Med Oncol, Columbus, OH USA
[3] UPMC Hillman Canc Ctr, Pittsburgh, PA USA
[4] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA
来源：
CLINICAL CANCER RESEARCH | 2024年 / 30卷 / 01期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1158/1078-0432.CCR-23-2437
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In this CCR Translations, we discuss the therapeutic potential of CD40 agonism, which stimulates antigen-presenting cells (APC) to activate effector T and NK cells. CD40 agonism may lead to development of an interferon-activated, T cell-inflamed tumor microenvironment and has the potential to facilitate long-term response with immune checkpoint blockade.
引用
收藏
页码：9 / 11
页数：3
相关论文
共 50 条
  • [1] Harnessing the potential of CD40 agonism in cancer therapy
    Zhou, Yang
    Richmond, Ann
    Yan, Chi
    CYTOKINE & GROWTH FACTOR REVIEWS, 2024, 75 : 40 - 56
  • [2] Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity
    Morrison, Alexander H.
    Diamond, Mark S.
    Hay, Ceire A.
    Byrne, Katelyn T.
    Vonderheide, Robert H.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2020, 117 (14) : 8022 - 8031
  • [3] Activating Immune Recognition in Pancreatic Ductal Adenocarcinoma via Autophagy Inhibition, MEK Blockade, and CD40 Agonism
    Jiang, Honglin
    Courau, Tristan
    Borison, Joseph
    Ritchie, Alexa J.
    Mayer, Aaron T.
    Krummel, Matthew F.
    Collisson, Eric A.
    GASTROENTEROLOGY, 2022, 162 (02) : 590 - +
  • [4] DUAL TARGETING OF IL-6 AND CD40 OVERCOMES GLIOBLASTOMA RESISTANCE TO IMMUNE CHECKPOINT BLOCKADE
    Yang, Fan
    Brem, Steven
    Fan, Yi
    NEURO-ONCOLOGY, 2020, 22 : 107 - 107
  • [5] The immune checkpoint regulator CD40 potentiates myocardial inflammation
    Jesus Jimenez
    Junedh Amrute
    Pan Ma
    Xiaoran Wang
    Shibali Das
    Raymond Dai
    Yohei Komaru
    Andreas Herrlich
    Matthias Mack
    Kory J. Lavine
    Nature Cardiovascular Research, 2025, 4 (4): : 458 - 472
  • [6] To respond or not to respond to CD40 agonism That is the prediction
    Shi, Xiaoyan
    Dornan, David
    ONCOIMMUNOLOGY, 2012, 1 (01): : 83 - 85
  • [7] Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint
    Tang, TingTing
    Cheng, Xiang
    Truong, Billy
    Sun, LiZhe
    Yang, XiaoFeng
    Wang, Hong
    PHARMACOLOGY & THERAPEUTICS, 2021, 219
  • [8] CD40 ligand blockade
    Frances Williams
    Arthritis Research & Therapy, 3 (1)
  • [9] Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer
    Rech, Andrew J.
    Dada, Hannah
    Kotzin, Jonathan J.
    Henao-Mejia, Jorge
    Minn, Andy J.
    Victor, Christina Twyman-Saint
    Vonderheide, Robert H.
    CANCER RESEARCH, 2018, 78 (15) : 4282 - 4291
  • [10] REGULATING NEGATIVE IMMUNE REGULATORS TO ENHANCE IMMUNE CHECKPOINT BLOCKADE ANTITUMOR POTENTIAL
    Hailemichael, Yared
    Winn, Glenn
    Davies, Michael
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A953 - A953
12345